381 related articles for article (PubMed ID: 26527687)
21. In Vitro Biochemical Assays for O-GlcNAc-Processing Enzymes.
Kim EJ
Chembiochem; 2017 Aug; 18(15):1462-1472. PubMed ID: 28474822
[TBL] [Abstract][Full Text] [Related]
22. O-GlcNAcylation increases ChREBP protein content and transcriptional activity in the liver.
Guinez C; Filhoulaud G; Rayah-Benhamed F; Marmier S; Dubuquoy C; Dentin R; Moldes M; Burnol AF; Yang X; Lefebvre T; Girard J; Postic C
Diabetes; 2011 May; 60(5):1399-413. PubMed ID: 21471514
[TBL] [Abstract][Full Text] [Related]
23. A Conserved Splicing Silencer Dynamically Regulates O-GlcNAc Transferase Intron Retention and O-GlcNAc Homeostasis.
Park SK; Zhou X; Pendleton KE; Hunter OV; Kohler JJ; O'Donnell KA; Conrad NK
Cell Rep; 2017 Aug; 20(5):1088-1099. PubMed ID: 28768194
[TBL] [Abstract][Full Text] [Related]
24. O-GlcNAcylation of RBM14 contributes to elevated cellular O-GlcNAc through regulation of OGA protein stability.
Kweon TH; Jung H; Ko JY; Kang J; Kim W; Kim Y; Kim HB; Yi EC; Ku NO; Cho JW; Yang WH
Cell Rep; 2024 May; 43(5):114163. PubMed ID: 38678556
[TBL] [Abstract][Full Text] [Related]
25. Short O-GlcNAcase Is Targeted to the Mitochondria and Regulates Mitochondrial Reactive Oxygen Species Level.
Pagesy P; Bouaboud A; Feng Z; Hulin P; Issad T
Cells; 2022 Jun; 11(11):. PubMed ID: 35681522
[TBL] [Abstract][Full Text] [Related]
26. Identification and characterization of a missense mutation in the
Vaidyanathan K; Niranjan T; Selvan N; Teo CF; May M; Patel S; Weatherly B; Skinner C; Opitz J; Carey J; Viskochil D; Gecz J; Shaw M; Peng Y; Alexov E; Wang T; Schwartz C; Wells L
J Biol Chem; 2017 May; 292(21):8948-8963. PubMed ID: 28302723
[No Abstract] [Full Text] [Related]
27. Yeast cells as an assay system for in vivo O-GlcNAc modification.
Nakanishi H; Li F; Han B; Arai S; Gao XD
Biochim Biophys Acta Gen Subj; 2017 May; 1861(5 Pt A):1159-1167. PubMed ID: 28263870
[TBL] [Abstract][Full Text] [Related]
28. Changes in O-Linked N-Acetylglucosamine (O-GlcNAc) Homeostasis Activate the p53 Pathway in Ovarian Cancer Cells.
de Queiroz RM; Madan R; Chien J; Dias WB; Slawson C
J Biol Chem; 2016 Sep; 291(36):18897-914. PubMed ID: 27402830
[TBL] [Abstract][Full Text] [Related]
29. Mutations in
Willems AP; Gundogdu M; Kempers MJE; Giltay JC; Pfundt R; Elferink M; Loza BF; Fuijkschot J; Ferenbach AT; van Gassen KLI; van Aalten DMF; Lefeber DJ
J Biol Chem; 2017 Jul; 292(30):12621-12631. PubMed ID: 28584052
[No Abstract] [Full Text] [Related]
30. OGT-mediated O-GlcNAcylation promotes NF-κB activation and inflammation in acute pancreatitis.
Zhang D; Cai Y; Chen M; Gao L; Shen Y; Huang Z
Inflamm Res; 2015 Dec; 64(12):943-52. PubMed ID: 26407569
[TBL] [Abstract][Full Text] [Related]
31. Caenorhabditis elegans ortholog of a diabetes susceptibility locus: oga-1 (O-GlcNAcase) knockout impacts O-GlcNAc cycling, metabolism, and dauer.
Forsythe ME; Love DC; Lazarus BD; Kim EJ; Prinz WA; Ashwell G; Krause MW; Hanover JA
Proc Natl Acad Sci U S A; 2006 Aug; 103(32):11952-7. PubMed ID: 16882729
[TBL] [Abstract][Full Text] [Related]
32. The role of the retinoblastoma/E2F1 tumor suppressor pathway in the lesion recognition step of nucleotide excision repair.
Lin PS; McPherson LA; Chen AY; Sage J; Ford JM
DNA Repair (Amst); 2009 Jul; 8(7):795-802. PubMed ID: 19376752
[TBL] [Abstract][Full Text] [Related]
33. Cryo-EM structure of human O-GlcNAcylation enzyme pair OGT-OGA complex.
Lu P; Liu Y; He M; Cao T; Yang M; Qi S; Yu H; Gao H
Nat Commun; 2023 Oct; 14(1):6952. PubMed ID: 37907462
[TBL] [Abstract][Full Text] [Related]
34. The E2F-1 associated retinoblastoma-susceptibility gene product is modified by O-GlcNAc.
Wells L; Slawson C; Hart GW
Amino Acids; 2011 Mar; 40(3):877-83. PubMed ID: 20680651
[TBL] [Abstract][Full Text] [Related]
35.
Zhang Z; Parker MP; Graw S; Novikova LV; Fedosyuk H; Fontes JD; Koestler DC; Peterson KR; Slawson C
J Biol Chem; 2019 Jan; 294(4):1363-1379. PubMed ID: 30523150
[TBL] [Abstract][Full Text] [Related]
36. Excessive
Umapathi P; Mesubi OO; Banerjee PS; Abrol N; Wang Q; Luczak ED; Wu Y; Granger JM; Wei AC; Reyes Gaido OE; Florea L; Talbot CC; Hart GW; Zachara NE; Anderson ME
Circulation; 2021 Apr; 143(17):1687-1703. PubMed ID: 33593071
[TBL] [Abstract][Full Text] [Related]
37. Overview of the Assays to Probe
Balsollier C; Pieters RJ; Anderluh M
Molecules; 2021 Feb; 26(4):. PubMed ID: 33669256
[No Abstract] [Full Text] [Related]
38. O-GlcNAcase targets pyruvate kinase M2 to regulate tumor growth.
Singh JP; Qian K; Lee JS; Zhou J; Han X; Zhang B; Ong Q; Ni W; Jiang M; Ruan HB; Li MD; Zhang K; Ding Z; Lee P; Singh K; Wu J; Herzog RI; Kaech S; Wendel HG; Yates JR; Han W; Sherwin RS; Nie Y; Yang X
Oncogene; 2020 Jan; 39(3):560-573. PubMed ID: 31501520
[TBL] [Abstract][Full Text] [Related]
39. mTOR/MYC Axis Regulates O-GlcNAc Transferase Expression and O-GlcNAcylation in Breast Cancer.
Sodi VL; Khaku S; Krutilina R; Schwab LP; Vocadlo DJ; Seagroves TN; Reginato MJ
Mol Cancer Res; 2015 May; 13(5):923-33. PubMed ID: 25636967
[TBL] [Abstract][Full Text] [Related]
40. Sustained
Tan EP; McGreal SR; Graw S; Tessman R; Koppel SJ; Dhakal P; Zhang Z; Machacek M; Zachara NE; Koestler DC; Peterson KR; Thyfault JP; Swerdlow RH; Krishnamurthy P; DiTacchio L; Apte U; Slawson C
J Biol Chem; 2017 Sep; 292(36):14940-14962. PubMed ID: 28739801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
